Literature DB >> 23451000

The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis.

Johannes Wiegand1, Thomas Berg.   

Abstract

BACKGROUND: Cirrhosis of the liver is the end stage of chronic liver disease. Among the many liver disorders that can lead to cirrhosis, some progress rapidly (years) and others more slowly (decades). In Germany, cirrhosis is often a consequence of fatty liver disease due to alcoholism or other causes, but can also be caused by hepatitis B and hepatitis C. Cirrhosis is more common in overweight persons and smokers. The underlying causes of cirrhosis determine its rate of progression and are the focus of preventive efforts and treatment. The prevalence of cirrhosis in Germany is rising; it now ranks among the top 20 causes of death in the country.
METHODS: This article is based on a selective review of pertinent literature, including reviews and current guidelines.
RESULTS: Strictly speaking, cirrhosis is a pathological diagnosis; it is, nevertheless, usually diagnosed clinically, by history, physical examination (e.g., cutaneous signs of liver disease), ancillary testing (e.g., ultrasonography, transient elastography) and laboratory analyses (e,g., APRI, which is the quotient of the GOT concentration and the platelet count). There are no laboratory cutoff values for the diagnosis of cirrhosis. Early detection of chronic liver disease, followed by individually tailored, risk-adapted treatment, is the best way to prevent it. Esophagogastroduodenoscopy can be performed early on to assess the risk of variceal bleeding. In most patients, the progression of fibrosis can be averted by early detection and appropriate treatment.
CONCLUSION: Screening for chronic liver disease should include history and physical examination, serum transaminase measurement, upper abdominal ultrasonography, and, in some cases, transient elastography.

Entities:  

Mesh:

Year:  2013        PMID: 23451000      PMCID: PMC3583179          DOI: 10.3238/arztebl.2013.0085

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  41 in total

Review 1.  [Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet)].

Authors:  P Schirmacher; W E Fleig; A Tannapfel; C Langner; V Dries; L Terracciano; H Denk; H P Dienes
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

2.  APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C.

Authors:  Ned Snyder; Leka Gajula; Shu-Yuan Xiao; James Grady; Bruce Luxon; Daryl T-Y Lau; Roger Soloway; John Petersen
Journal:  J Clin Gastroenterol       Date:  2006-07       Impact factor: 3.062

3.  Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests.

Authors:  Carolin Lackner; Gerd Struber; Csilla Bankuti; Bernd Bauer; Rudolf E Stauber
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

4.  Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center.

Authors:  Venodhar R Julapalli; Jennifer R Kramer; Hashem B El-Serag
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

5.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.

Authors:  F Imbert-Bismut; V Ratziu; L Pieroni; F Charlotte; Y Benhamou; T Poynard
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

Review 6.  Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors:  Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  Serum markers detect the presence of liver fibrosis: a cohort study.

Authors:  William M C Rosenberg; Michael Voelker; Robert Thiel; Michael Becka; Alastair Burt; Detlef Schuppan; Stefan Hubscher; Tania Roskams; Massimo Pinzani; Michael J P Arthur
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

8.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

Review 9.  The indications for liver biopsy.

Authors:  Andrea Tannapfel; Hans-Peter Dienes; Ansgar W Lohse
Journal:  Dtsch Arztebl Int       Date:  2012-07-09       Impact factor: 5.594

10.  FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

Authors:  Anaïs Vallet-Pichard; Vincent Mallet; Bertrand Nalpas; Virginie Verkarre; Antoine Nalpas; Valérie Dhalluin-Venier; Hélène Fontaine; Stanislas Pol
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

View more
  45 in total

Review 1.  Management of patients with risk factors.

Authors:  Frank Waldfahrer
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13

2.  Liver cirrhosis, transplantation and organ shortage.

Authors:  Michael P Manns
Journal:  Dtsch Arztebl Int       Date:  2013-02-08       Impact factor: 5.594

Review 3.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study.

Authors:  Chun Wang; Hie-Won Hann; Richard S Hann; Shaogui Wan; Ronald E Myers; Zhong Ye; Jinliang Xing; Hushan Yang
Journal:  Dig Dis Sci       Date:  2015-01-15       Impact factor: 3.199

Review 5.  Pathophysiology and Management of Variceal Bleeding.

Authors:  Saleh A Alqahtani; Sunguk Jang
Journal:  Drugs       Date:  2021-03-12       Impact factor: 9.546

Review 6.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

Review 7.  Arrhythmia risk in liver cirrhosis.

Authors:  Ioana Mozos
Journal:  World J Hepatol       Date:  2015-04-08

Review 8.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

9.  Inhibitory effects of rapamycin on the different stages of hepatic fibrosis.

Authors:  Yun Jeung Kim; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee; Seung Moo Noh; Dae Young Kang; Byung Seok Lee
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects.

Authors:  Monica Acalovschi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.